Tag Archives: diabetes mellitus
June 2018 Br J Cardiol 2018;25:73–6 doi:10.5837/bjc.2018.016
Prescribing glucose-lowering drugs for patients with cardiac disease
Miles Fisher, Emma Johns, Gerry McKay
(more…)
March 2018 doi:10.5837/bjc.2018.007
Older antidiabetic drugs
Emma Johns, Gerry McKay, Miles Fisher
(more…)
November 2017 Br J Cardiol 2017;24:152–5 doi:10.5837/bjc.2017.030
Glucagon-like peptide-1 (GLP-1) receptor agonists
Emma Johns, Gerry McKay, Miles Fisher
(more…)
July 2017 Br J Cardiol 2017;24:113–16 doi:http://doi.org/10.5837/bjc.2017.018 Online First
Glitazones (thiazolidinediones)
Emma Johns, Gerry McKay, Miles Fisher
(more…)
April 2017 Br J Cardiol 2017;24:68-71 doi:10.5837/bjc.2017.010 Online First
SGLT2 inhibitors
Emma Johns, Gerry McKay, Miles Fisher
(more…)
January 2017 Br J Cardiol 2017;24:(1) doi:10.5837/bjc.2017.001 Online First
Dipeptidyl peptidase-4 (DPP-4) inhibitors
Emma Johns, Gerry McKay, Miles Fisher
(more…)
November 2007 Br J Cardiol 2007;14:267-71
The JBS 2 guidelines for the prevention of cardiovascular disease in people with diabetes: an approach to implementation
James D Lee, Sakera Shaikh, John R Morrissey, Vinod Patel
The need for new guidelines The aim of the first guidelines from the Joint British Societies (JBS 1) was to promote a more effective multi-disciplinary approach to cardiovascular disease (CVD) prevention.4 The guidelines addressed the needs of both individuals with established disease and apparently healthy subjects at high risk of developing disease. The National Service Framework for Coronary Heart Disease (CHD) for England and Wales endorsed the lifestyle and risk factor targets in JBS 1.5 It also established national audit standards, which were subsequently reinforced and expanded by the General Medical Services contract for primary care.
September 2004 Br J Cardiol 2004;11:379-86
Cocoa, flavanols and cardiovascular risk
Norman K Hollenberg, Harold Schmitz, Ian MacDonald, Neil Poulter
No content available
For healthcare professionals only
